Feb. 17 at 3:21 PM
PickAlpha Midday:
Bayer is reportedly preparing a
$10.5B Roundup settlement push to address both current and future cancer claims, signaling a renewed attempt to force litigation finality.  The backdrop is still heavy: Bayer has already paid about
$10B, still faces roughly 67,000 pending cases, and the U.S. Supreme Court has agreed to hear its appeal in a key
$1.25M Missouri case. 
Tickers:
$BAYRY
Our view is this is an overhang-clearance catalyst, not a full all-clear yet. If Bayer secures durable “future claims” protection and keeps funding contained, the valuation gap can compress; if finality gets challenged in court, the legal discount likely sticks.